Qureight Fibr8 biyomarkeri, PROPEL-IPF Faz 2 denemesinde ikincil uç nokta seçildi

Qureight'in Fibr8 biyomarkeri, Contineum hastalarında PIPE-791'in güvenlik ve etkinlik araştıran PROPEL-IPF Faz 2 denemesinde ikincil uç nokta seçildi.

· 1 dk 2 Qureight Fibr8 biyomarkeri, PROPEL-IPF Faz 2 denemesinde ikincil uç nokta seçildi Sessiz Estetik Dönemi: Ameliyat Olduğu Anlaşılmayan Doğal Görünümün Sırrı Qureight, an end-to-end imaging company providing enterprise-grade imaging and precision endpoints for clinical trials for lung and heart disease, and Contineum Therapeutics, Inc. (Contineum), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today announced that Qureight's Fibr8™ quantitative imaging biomarker is being used as a secondary endpoint in Contineum's PROPEL-IPF Phase 2 clinical trial examining the safety and efficacy of PIPE-791, Contineum's lead drug candidate, in idiopathic pulmonary fibrosis (IPF) patients.